Brought to you by 
Follow-on nets $95.9mm for bluebird bio
09 Jul 2014
Executive Summary
Just one week after acquiring Precision Genome Engineering Inc., bluebird bio Inc. (gene therapies for genetic and orphan diseases) netted $95.9mm through the follow-on public sale of 3mm common shares at $34 each. Proceeds will help fund a Phase II/III trial for Lenti-D in childhood cerebral adrenoleukodystrophy and a Phase I/II study of LentiGlobin for beta-thalassemia major and sickle cell disease.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Follow-on nets $95.9mm for bluebird bio
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice